• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A

    Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A

  2. Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

    Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

  3. Phase III Study Shows Genentech ’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

    Phase III Study Shows Genentech ’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

  4. Global Acquired Hemophilia Treatment Market 2013-2015 & 2016-2023 - Research and Markets

    Global Acquired Hemophilia Treatment Market 2013-2015 & 2016-2023 - Research and Markets

  5. UPDATE: You can now find out your genetic risks for disease for $200, without a doctor

    UPDATE: You can now find out your genetic risks for disease for $200, without a doctor

  6. FDA Advisory Committee Unanimously Recommends Approval of Genentech ’s Subcutaneous Rituximab for Certain Blood Cancers

    FDA Advisory Committee Unanimously Recommends Approval of Genentech ’s Subcutaneous Rituximab for Certain Blood Cancers

  7. FDA OKs Genentech multiple-sclerosis drug Ocrevus

    FDA OKs Genentech multiple-sclerosis drug Ocrevus

  8. Public Statement from the Hillman Family, The Hillman Company and Hillman Family Foundations on the Passing of Henry L. Hillman

    Public Statement from the Hillman Family, The Hillman Company and Hillman Family Foundations on the Passing of Henry L. Hillman

  9. China's Desert Hamsters on Medicine's Front Line

    China's Desert Hamsters on Medicine's Front Line

  10. You can soon find out your genetic risks for disease for $200, without a doctor

    You can soon find out your genetic risks for disease for $200, without a doctor

12345

©2017 Morningstar Advisor. All right reserved.